The Lexiebean Foundation, Current News

Giving those affected by Cystic Fibrosis reason to Believe

Current News

11/14/17
Caregiver burden of parents of young children with cystic fibrosis

There is a paucity of research examining the impact of informal caregiving on parents of young children with cystic fibrosis (CF). The aim of this study was to examine caregiver burden and identify risk factors associated with high caregiver burden in mothers and fathers of young children with CF.

11/8/17
Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial

Intestinal dysbiosis has been described in Cystic Fibrosis (CF) and probiotics have been proposed to restore microbial composition. Aim of the study was to investigate the effects of Lactobacillus rhamnosus GG (LGG) on clinical outcomes in children with cystic fibrosis (CF).

11/8/17
Fecal calprotectin concentrations in young children with cystic fibrosis: Authors response

We would like to thank Ellemunter et al. [1] for their interest in our study regarding age-related levels of fecal calprotectin in children with cystic fibrosis (CF), less than ten years old [2]. We congratulate Ellemunter et al. [3] for publishing a study on fecal calprotectin in patients with CF based on a large sample size and wide range of ages, 0 to 61years old.

11/8/17
Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR

Evaluation of the safety, tolerability, and efficacy of lumacaftor/ivacaftor in patients with cystic fibrosis (CF) with severe lung disease.

11/2/17
Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis

Methicillin-resistant Staphylococcus aureus (MRSA) is a prevalent pathogen in patients with cystic fibrosis (CF) associated with increased morbidity. Ceftaroline fosamil is an intravenous (IV) cephalosporin with activity against MRSA. There are minimal data regarding dosing in the CF population. The objective of this study was to determine the pharmacokinetic and pharmacodynamic profile of IV ceftaroline in patients with CF.

10/31/17
Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation

Patients with cystic fibrosis (CF) experience variable lung disease phenotypes. The R117H mutation is often associated with preserved lung function. Our objective was to compare the rate of lung function decline in patients with the R117H mutation and patients homozygous for the F508del mutation.

10/30/17
Defining palliative care in cystic fibrosis: A Delphi study

The goal of palliative care is to improve quality of life for people with serious illness. We aimed to create a cystic fibrosis (CF)-specific definition of palliative care.